TY  - JOUR 
AU  - Belhassen García, Moncef
AU  - Sánchez-Puente, Antonio
AU  - Dorado Díaz, Pedro Ignacio
AU  - López Bernús, Amparo
AU  - Sampedro-Gómez, Jesús
AU  - Azibeiro-Melchor, Raúl
AU  - Marcano-Millán, Edgar
AU  - Rodríguez-Alonso, Beatriz
AU  - Sánchez-Barrado, María-Elisa
AU  - Hernández-García, Ignacio
AU  - Madruga, Ignacio
AU  - Hernández-Pérez, Guillermo
AU  - Carbonell, Cristina
AU  - García Aparicio, Judit
AU  - Burgos, Laura
AU  - López-Sánchez, Eugenia
AU  - Reina, Carlos
AU  - Ramón, Ana-María
AU  - Cestero-Ramírez, Laura
AU  - Boumhir, Fátima
AU  - Encinas-Sánchez, Daniel
AU  - Sánchez-Ledesma, María
AU  - Herráez, Jacinto
AU  - Araoz, Patricia
AU  - Sánchez-Crespo, María-José
AU  - Rodríguez-Rodríguez, Sandra
AU  - Rodríguez-Gude, Ana-Elisa
AU  - Sánchez-Hernández, Miguel-Vicente
AU  - Borrás Beato, Rafael
AU  - Sagredo-Meneses, Víctor
AU  - Sánchez Fernández, Pedro Luis
AU  - Marcos, Miguel
AU  - Martín Oterino, José Ángel
PY  - 2021
SN  - 2077-0383
UR  - http://hdl.handle.net/10366/162020
AB  - [EN]The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose...
LA  - eng
PB  - MDPI
KW  - COVID-19
KW  - SARS-CoV-2
KW  - Infectious diseases
KW  - Machine learning
KW  - Tocilizumab
KW  - Corticosteroids
TI  - Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone.
DO  - 10.3390/jcm11010198
T2  - Journal of clinical medicine
VL  - 11
ER  -